Navigation Links
ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
Date:2/6/2008

ch and

development 1,617,000 973,000 3,113,000 1,935,000

Total operating

expenses 3,974,000 3,273,000 7,890,000 6,547,000

Interest and other

income 347,000 454,000 754,000 920,000

Net loss ($1,717,000) ($2,030,000) ($4,017,000) ($3,126,000)

Basic and diluted

net loss per

common share ($0.03) ($0.04) ($0.07) ($0.06)

Shares used in

computing per share

data 55,701,175 55,140,675 55,680,342 55,022,221

THERMOGENESIS CORP.

Condensed Statements of Cash Flows

(Unaudited)

Six Months Ended

December 31,

2007 2006

Cash flows from operating activities:

Net loss ($4,017,000) ($3,126,000)

Adjustments to reconcile net loss to net

cash used in operating activities:

Depreciation and amortization 265,000 228,000

Stock based compensation expense 1,121,000 582,000

Accretion of discount on short-term

investments (564,000) (690,000)

Net change in operating assets and liabilities:

Accounts receivable, net 123,000 376,000

Inventories, net (191,000) (1,542,000)

Other current assets 204,000 138,000

Other assets 45,000 (15,000)

Accounts payable (434,000) 618,000

Accrued payroll and related expenses (
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
7. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
8. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
9. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
10. Helix BioPharma Corp. announces fiscal 2007 results
11. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
Post Your Comments:
*Name:
*Comment:
*Email: